There are many ways to assess heart disease risk, including lipid and cholesterol measures. The focus of this article is HDL-Cholesterol, but I have written similar articles about LDL-Cholesterol (available here) and Triglycerides (available here).
What Is HDL-Cholesterol?
High density lipoprotein (HDL) is a carrier molecule for cholesterol, phospholipids and triglycerides.
Think of HDL as a boat.
Cholesterol is the cargo.
Remember the cholesterol (cargo) can’t float in the blood; it needs to be carried around by the lipoprotein (the boat). Therefore, HDL-C is how much cholesterol (cargo) is on the HDL (boat). There can be varying amounts of cargo on each boat. As you’ll soon learn, it is beneficial to have a high HDL-C. In other words we want a lot of cargo on the HDL boats.
HDL can carry varying amounts of cholesterol. In fact, its benificial to have a higher HDL-C.
What Does HDL Do?
HDL carries cholesterol away from cells and takes it to the liver to either be removed from the body or reused. The process of taking cholesterol from the peripheral tissues back to the liver is called reverse cholesterol transport , . On the other hand, low density lipoprotein (LDL), takes cholesterol to the cells. The reason LDL is considered ‘bad’ is because when cholesterol is attached to it, that cholesterol is susceptible to damage and may contribute to atherosclerosis, and subsequently heart disease.
It’s important to remember cholesterol is not inherently bad, it just happens to be susceptible to damage. In fact, click here to learn about the Truth About Cholesterol and Eggs and click here for an article about How We Got Misled about Cholesterol.
Why Do We Want to Increase HDL-C?
As mentioned above, HDL basically cleans up the blood and cells of cholesterol, thus minimizing the cholesterol’s chance of being oxidized or damaged.
There are many established risk factors for heart disease. Diagnoses such as obesity, diabetes, kidney disease, and hypertension are just a few co-morbidities that increase cardiovascular disease risk . Certain blood lipids will be tested and associated with risk. HDL-C is considered a negative risk factor  – meaning it protects against heart disease .
HDL is anti-inflammatory , , minimizes oxidative stress  , inhibits cells in the blood from sticking to each other  and possibly plays a role in improving diabetes and glucose metabolism  . So you can see why we want HDL to be high. For HDL to have its protective effect, we aim to keep it above 1.55 mmol/L (60 mg/dL) .
Low HDL-C is associated with hypertriglyceridemia, diabetes, overweight/obesity, physical inactivity, cigarette smoking, very high carbohydrate intake, certain drugs (beta-adrenergic blockers, anabolic steroids, progestational agents), and genetic factors .
Diet Interventions that Increase HDL-C
1. Lower Carb/Higher Fat Diets
- Lowers triglycerides, raises HDL-C 
- LDL-C may not change in concentration but the molecule shifts to the larger, buoyant one 
- Low carbohydrate = less than 50 grams a day (or less than 10% of total energy)
- High fat diets have very few reported adverse effects and little to no effect on blood lipid levels
- Added benefit – more weight loss than low-fat diets over 6 months 
- Low carb/high fat diet on obesity (still low calorie diet): improve HDL, lowers inflammatory markers (CRP) 
- Low carb/high fat diet on Metabolic Syndrome: extreme improvement in LDL, body weight, BMI, waist circumference, fasting blood sugar, triglycerides, blood pressure, and HDL 
- Low carb/high fat diet on Type 2 Diabetes: substantial improvements to weight loss, HbA1c, fasting glucose, blood glucose stability, reduced diabetes medications needed, better lipid profiles (increased HDL, reduced triglycerides) 
2. Influences of Dietary Fat on Blood Lipids
- Fatty fish reduces triglycerides; helps HDL, LDL, blood pressure  ; reduces triglycerides in both hyper- and normo-triglyceride populations 
- Eating fish at least 4 times a week increases HDL in those with heart disease 
- Avoid artificial hydrogenated Polyunsaturated Fatty Acids (vegetable oils such as corn, soybean oil, margarine, canola)
o Studies show they reduce HDL  and worsen LDL profiles 
- Avoid trans-fats
o Raise TC and LDL-C; lower HDL-C , 
o Sources of TFAs are partial hydrogenation of vegetable oils: margarines, shortenings, commercially fried foods, baked good
3. Soluble Fiber helps HDL
- Soluble fiber is the non-digestible carbohydrate component of plants, and it has an inverse association with cardiovascular disease risk 
- Examples are: Beans, oats, barley, fruits, vegetables
- Additional 5-10 grams per day to one’s diet may reduce LDL-C by about 5%
4. Plant sterols (stanols/sterols)
- Phyosterols come from nuts, seeds, vegetable oils 
- Phyosterols lower LDL-C independent of dietary cholesterol intake
- Supplements exist which provide a dose required to have this therapeutic effect
- Helpful for use with statin drugs, especially when statins are about to increase in dose. Try adding this instead 
3. Olive Oil
- 15 grams was able to protect LDL from oxidation and raise HDL  and lower total cholesterol-to-HDL ratio, lower triglyceride levels and lower oxidative markers 
- Improves antioxidant status: glutathione, superoxide dismutase, catalase 
- Polyphenol content is important; so find brands that have high amounts of polyphenols
Foods that Increase HDL-C
- In both low risk and high risk heart disease patient, have been shown to increase HDL and lower LDL’s contribution to atherosclerosis 
- 10 grams before breakfast, in patients with coronary artery disease increased HDL by about 15%
4. Coconut oil
- Types of fat matter – high saturated versus low saturated fat improved LDL:HDL ratio 
- In obesity – improved HDL, LDL, triglycerides (hypocaloric diet), also reduction in adiposity 
5. Anthocyanin (berries)
- Omega-3 fatty acids EPA and DHA – sources are fish oil, fortified foods, supplements
- Magnesium not only increases HDL-C, but it lowers LDL-C and triglyceride levels 
- Improves HDL and Total Cholesterol/HDL ratio and inhibits LDL-C oxidation
- Helpful in both prevention and treatment of coronary artery disease 
Lifestyle Factors that Increase HDL-C?
- High intensity exercise is best for blood pressure, lipoproteins and triglycerides compared to endurance alone or low intensity exercise 
- Aerobic exercise is effective too – TG reduction by 12%, HDL-C increase of 4.1% in overweight, obese individuals
2. Weight loss
- 5-10% weight loss results in 15% reduction of LDL, 20% reduction of triglycerides and 8-10% increase in HDL-C 
- For some, during the weight loss phase, HDL may go down, but once weight loss is maintained it will normalize, higher than it was 
- Especially in obese/overweight people, alternate day fasting and endurance exercise. Body mass index reduced, fat mass, waist circumference decreased, lean mass retained, LDL particle increased, HDL increased 
- 3% weight loss is enough in obese and overweight people to see improvements to all cholesterol, liver function, and sugar levels 
3. Limit Alcohol and drink wisely
- Alcohol has both positive and negative associations to heart disease risk
- Overconsumption leads to alcoholism, hypertension, obesity, stroke, breast cancer, suicide, and accidents
- alcohol lowers fibrinogen (a clotting factor) – which would therefore reduce certain risks 
- The recommendation is to continue drinking responsibly but not to start drinking just to gain this benefit
Take Home Message
HDL is a very important lipid marker and a strong predictor of overall heart health. There are a number of ways known to significantly affect HDL-cholesterol levels, from diet and food to supplements.
For more information about supplements, and for a more indepth discussion and analysis into your heart health, book in by clicking here.
Click to expand
 Z. Clayton, E. Fusco and M. Kern, “Egg consumption and heart health: A review.,” Nutritiom, vol. 10.1016/j.nut.2016.12.014, pp. 79-85, 2017. [https://www.ncbi.nlm.nih.gov/pubmed/28359368].
 M. Kanter, P. Kris-Etherton, M. Fernandez, K. Vickers and D. Katz, “Exploring the Factors That Affect Blood Cholesterol and Heart Disease Risk: Is Dietary Cholesterol as Bad for You as History Leads Us to Believe?,” Advances in Nutrition, vol. 3, pp. 711-717, 2012. [http://advances.nutrition.org/content/3/5/711.full].
 P. Jellinger, Y. Handelsman, P. Rosenblit, Z. Bloomgarden, V. Fonseca, A. Garber, G. Grunberger, C. Guerin, D. Bell, J. Mechanick, R. Pessah-Pollack, K. Wyne, D. Smith, E. Brinton, S. Fazio and M. Davidson, “AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.,” Endocrine Practice, vol. 23, no. 2, pp. 1-87, 2017. [https://www.ncbi.nlm.nih.gov/pubmed/28437620].
 D. Rader, E. Alexander, G. Weibel, J. Billheimer and G. Rothblat, “The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis.,” J Lipid Res., Vols. doi: 10.1194/jlr.R800088-JLR200, pp. 189-194, 2009. [https://www.ncbi.nlm.nih.gov/pubmed/19064999].
 F. Tabet and K. Rye, “High-density lipoproteins, inflammation and oxidative stress,” Clincial Science, vol. 116, no. 2, pp. 87-98, 2009. [http://www.clinsci.org/content/116/2/87].
 B. Drew, N. Fidge, G. Gallon-Beaumier, B. Kemp and B. Kingwell, “High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation,” PNAS, vol. 101, no. 18, pp. 6999-7004, 2004. [http://www.pnas.org/content/101/18/6999.abstract?ijkey=8072a08e3d88fe1982160a3cc0bb07a7bf4b2790&keytype2=tf_ipsecsha].
 J. Nofer, M. Brodde and B. Kehrel, “High-density lipoproteins, platelets and the pathogenesis of atherosclerosis,” Clinical and Experimental Pharmacology and Physiology, vol. 37, no. 7, pp. 726-735, 2010. [http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1681.2010.05377.x/abstract;jsessionid=1D97A824355D367A9880CB74A9F53F72.f04t01].
 M. Fryirs, P. Barter, M. Appavoo, B. Tuch, F. Tabet, A. Heather and K. Rye, “Effects of High-Density Lipoproteins on Pancreatic β-Cell Insulin Secretion,” AHA Journals Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 1642-1648, 2010. [http://atvb.ahajournals.org/content/30/8/1642?ijkey=776d8ab3d9d18d5af2c5a70ed0b8f2bb440f10e1&keytype2=tf_ipsecsha].
 B. Drew, S. Duffy, M. Formosa and A. Natoli, “High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus,” Circulation, vol. 119, pp. 2103-2111, 2009. [http://circ.ahajournals.org/content/119/15/2103?ijkey=70636f4c19afc0657c2da0b08b8e92bb4206d5d0&keytype2=tf_ipsecsha].
 H. Katcher, A. Hill, J. Langford, J. Yoo and P. Kris-Etherton, “Lifestyle Approaches and Dietary Strategies to Lower LDL-Cholesterol and Triglycerides and Raise HDL-Cholesterol,” Endocrinology and Metabolism Clinics of North America, vol. 38, no. 1, pp. 45-78, 2009. [http://www.sciencedirect.com/science/article/pii/S0889852908000856].
 M. Ruth, A. Port, M. Shah and N. Gokce, “Consuming a hypocaloric high fat low carbohydrate diet for 12 weeks lowers C-reactive protein, and raises serum adiponectin and high density lipoprotein-cholesterol in obese subjects.,” Metabolism, vol. 62, no. 12, pp. 1779-1787, 2013. [https://www.ncbi.nlm.nih.gov/pubmed/24075505].
 J. Pérez-Guisado and A. Muñoz-Serrano, “A pilot study of the Spanish Ketogenic Mediterranean Diet: an effective therapy for the metabolic syndrome.,” J Med Food, vol. 14, no. 7-8, pp. 681-687, 2011. [https://www.ncbi.nlm.nih.gov/pubmed/21612461].
 J. Tay, C. Thompson, M. Noakes, J. Buckley and G. Brinkworth, “Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial.,” Am J Clin Nutr., vol. 102, no. 4, pp. 780-790, 2015. [https://www.ncbi.nlm.nih.gov/pubmed/26224300].
 M. Pedersen, C. Mølgaard, L. Hellgren and L. Lauritzen, “Effects of fish oil supplementation on markers of the metabolic syndrome.,” J Pediatr, vol. 157, no. 3, pp. 395-400, 2010. [https://www.ncbi.nlm.nih.gov/pubmed/20472253].
 T. Lee, P. Ivester, A. Hester, S. Sergeant, L. Case, T. Morgan, E. Kouba and F. Chilton, “The impact of polyunsaturated fatty acid-based dietary supplements on disease biomarkers in a metabolic syndrome/diabetes population.,” Lipids Health Dis, pp. doi: 10.1186/1476-511X-13-196., 2014. [https://www.ncbi.nlm.nih.gov/pubmed/25515553].
 A. Erkkilä, U. Schwab, S. Lehto, V. de Mello, A. Kangas, P. Soininen, M. Ala-Korpela and M. Uusitupa, “Tarik Cohen,” J Clin Lipidol., vol. 8, no. 1, pp. 126-133, 2014. [https://www.ncbi.nlm.nih.gov/pubmed/24528693].
 J. Pedersen, H. Muller, I. Seljeflot and B. Kirkhus, “Palm oil versus hydrogenated soybean oil: effects on serum lipids and plasma haemostatic variables.,” Asia Pac J Clin Nutr., vol. 14, no. 4, pp. 348-357, 2005. [https://www.ncbi.nlm.nih.gov/pubmed/16326641].
 J. Chardingny, F. Destaillats, A. Lock, R. Mensink, F. Joffre, J. German and J. Sebedio, “Do trans fatty acids from industrially produced sources and from natural sources have the same effect on cardiovascular disease risk factors in healthy subjects? Results of the trans Fatty Acids Collaboration (TRANSFACT) study.,” Am J Clin Nutr, vol. 87, no. 3, pp. 558-565, 2008. [https://www.ncbi.nlm.nih.gov/pubmed/18326592].
 H. Jamshed, F. Sultan, R. Iqbal and A. Gilani, “Dietary Almonds Increase Serum HDL Cholesterol in Coronary Artery Disease Patients in a Randomized Controlled Trial.,” J Nutr. , vol. 145, no. 10, pp. 2287-2292, 2015. [https://www.ncbi.nlm.nih.gov/pubmed/26269239].
 J. Marrugat, M. Covas, M. Fitó, H. Schröder, E. Miró-Casas, E. Gimeno, M. López-Sabater, R. de la Torre and M. Farré, “Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation–a randomized controlled trial.,” Eur J Nutr, vol. 43, no. 3, pp. 140-147, 2004. [https://www.ncbi.nlm.nih.gov/pubmed/15168036].
 M. Covas, K. Nyyssönen, H. Poulsen, J. Kaikkonen, Z. H. H. Kiesewetter, A. Gaddi, R. de la Torre, J. Mursu, H. Bäumler, S. Nascetti, J. Salonen, M. Fitó, J. Virtanen and J. Marrugat, “The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial.,” Ann Intern Med. , vol. 145, no. 5, pp. 333-341, 2008. [https://www.ncbi.nlm.nih.gov/pubmed/16954359].
 M. Oliveras-López, J. Molina, M. Mir, E. Rey, F. Martín and H. de la Serrana, “Extra virgin olive oil (EVOO) consumption and antioxidant status in healthy institutionalized elderly humans.,” Arch Gerontol Geriatr., vol. 57, no. 2, pp. 234-242, 2013. [https://www.ncbi.nlm.nih.gov/pubmed/23642776].
 H. Müller, A. Lindman, A. Brantsaeter and J. Pedersen, “The serum LDL/HDL cholesterol ratio is influenced more favorably by exchanging saturated with unsaturated fat than by reducing saturated fat in the diet of women.,” J Nutr. , vol. 133, no. 1, pp. 78-83, 2003. [https://www.ncbi.nlm.nih.gov/pubmed/12514271].
 M. Assunção, H. Ferreira, A. dos Santos, C. Cabral and T. Florêncio, “Effects of dietary coconut oil on the biochemical and anthropometric profiles of women presenting abdominal obesity.,” Lipids, vol. 44, no. 7, pp. 593-601, 2009. [https://www.ncbi.nlm.nih.gov/pubmed/19437058].
 D. Li, Y. Zhang, Y. Liu, R. Sun and M. Xia, “Purified anthocyanin supplementation reduces dyslipidemia, enhances antioxidant capacity, and prevents insulin resistance in diabetic patients.,” J Nutr., vol. 145, no. 4, pp. 742-748, 2015. [https://www.ncbi.nlm.nih.gov/pubmed/25833778].
 Y. Qin, M. Xia, J. Ma, Y. Hao, J. Liu, H. Mou, L. Cao and W. Ling, “Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects.,” Am J Clin Nutr. , vol. 90, no. 3, pp. 485-492, 2009. [https://www.ncbi.nlm.nih.gov/pubmed/19640950].
 A. Rosanoff and M. Seelig, “Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals.,” J Am Coll Nutr, vol. 23, no. 5, pp. 501-505, 2004. PMID: 15466951 [https://www.ncbi.nlm.nih.gov/pubmed/15466951].
 N. Aksoy, M. Aksoy, C. Bagci, H. Gergerlioglu, H. Celik, E. Herken, A. Yaman, M. Tarakcioglu, S. Soydinc, I. Sari and V. Davutoglu, “Pistachio intake increases high density lipoprotein levels and inhibits low-density lipoprotein oxidation in rats.,” Tohoku J Exp Med. , vol. 212, no. 1, pp. 43-48, 2007. PMID: 17464102 [https://www.ncbi.nlm.nih.gov/pubmed/17464102].
 A. Paoli, Q. Pacelli, T. Moro, G. Marcolin, M. Neri, G. Battaglia, G. Sergi, F. Bolzetta and A. Bianco, “Effects of high-intensity circuit training, low-intensity circuit training and endurance training on blood pressure and lipoproteins in middle-aged overweight men.,” Lipids Health Dis., Vols. doi: 10.1186/1476-511X-12-131., p. 131, 2013. [https://www.ncbi.nlm.nih.gov/pubmed/24004639].
 S. Bhutani, M. Klempel, C. Kroeger, J. Trepanowski and K. Varady, “Alternate day fasting and endurance exercise combine to reduce body weight and favorably alter plasma lipids in obese humans.,” Obesity (Silver Spring), vol. 21, no. 7, pp. 1370-1379, 2013. [https://www.ncbi.nlm.nih.gov/pubmed/23408502].
 A. Muramoto, M. Matsushita, A. Kato, N. Yamamoto, G. Koike, M. Nakamura, T. Numata, A. Tamakoshi and K. Tsushita, “Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan.,” Obes Res Clin Pract, vol. 8, no. 5, pp. 466-475, 2014. [https://www.ncbi.nlm.nih.gov/pubmed/25263836].
About the Author
I’m Johann de Chickera, a Naturopathic Doctor, practicing in Ontario, Canada. My clinical practice relies on keeping up with the most up-to-date research and continued education. This blog serves as a way to provide others with a compilation of everything I’ve learned along the way. Please click here if you’re local and want to see me in practice.